Ocular Therapeutix IncOCUL
Price$7.29Intrinsic value$6.1715% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $52.1M-18.3% YoYTTM through 30 Jun 2026
Net Income -$301.4MTTM through 30 Jun 2026
Free Cash Flow -$255.1MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-592.6%
Operating Margin-603.0%
Net Margin-579.1%

Returns

-58.0%ROE
-44.9%ROA

Balance Sheet Health

Current Ratio13.11x
Cash & Equivalents$598.6M

Quality Metrics

Altman Z-Score5.98
Piotroski F-Score1 / 9
FCF Margin-490.1%
Rule of 40-488.4
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $52M
Diluted EPS-$1.40TTM
'19'20'21'22'23'24'25
FY2025: $-1.42

Dividend

No dividend

Capital Allocation

Capex Intensity32.4%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.